{
  "items": "39",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Short Interest in Oculis Holding AG (NASDAQ:OCS) Increases By 105.6%",
      "url": "https://www.marketbeat.com/instant-alerts/short-interest-in-oculis-holding-ag-nasdaqocs-increases-by-1056-2025-12-27/",
      "time_published": "20251227T230920",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Short interest in Oculis Holding AG (NASDAQ:OCS) surged by 105.6% in December, reaching 101,167 shares, representing about 0.2% of the stock. MarketBeat analysts maintain a \"Moderate Buy\" consensus with an average price target of $41.50, despite the company remaining unprofitable with negative margins. Several institutional investors have also adjusted their positions, showing increased activity in Oculis shares.",
      "banner_image": "https://www.marketbeat.com/logos/oculis-holding-ag-logo-1200x675.jpg?v=20230510063742",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.932679"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.835698"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.948357"
        }
      ],
      "overall_sentiment_score": 0.138968,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.128347",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Discipline and Rules-Based Execution in OCS Response",
      "url": "https://news.stocktradersdaily.com/news_release/78/Discipline_and_Rules-Based_Execution_in_OCS_Response_122425083802_1766626682.html",
      "time_published": "20251224T203800",
      "authors": [
        "Rolland S."
      ],
      "summary": "This article analyzes Oculis Holding Ag (NYSE: OCS), highlighting a potential for long-term sentiment if near and mid-term strong sentiment holds. It identifies a mid-channel oscillation pattern and presents an exceptional 38.8:1 risk-reward short setup. The analysis includes three distinct trading strategies tailored for different risk profiles and holding periods, based on AI models.",
      "banner_image": "https://news.stocktradersdaily.com/media/693395_OCS_graph.jpg",
      "source": "Stock Traders Daily",
      "category_within_source": "General",
      "source_domain": "Stock Traders Daily",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.942551"
        },
        {
          "topic": "economy_macro",
          "relevance_score": "0.613646"
        }
      ],
      "overall_sentiment_score": 0.427727,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.406631",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Assessing Oculis Holding (NasdaqGM:OCS) Valuation After FDA Backing for OCS\u201105 and PIONEER Program Progress",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocs/oculis-holding/news/assessing-oculis-holding-nasdaqgmocs-valuation-after-fda-bac",
      "time_published": "20251223T120854",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Oculis Holding has seen its stock gain after favorable FDA feedback for its neuro ophthalmology candidate OCS-05, paving the way for pivotal trials in 2025 and 2026. Despite a 20% year-to-date share price increase and a more than doubling of shareholder returns over three years, the company's price-to-book ratio of 7.1x is considered high compared to peers and the broader pharmaceuticals industry, suggesting a premium is already being assigned to its pipeline potential. Investors interested in specialized healthcare could explore other options, considering the current valuation and potential risks.",
      "banner_image": "NULL",
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.917432"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.706463"
        },
        {
          "topic": "finance",
          "relevance_score": "0.631304"
        }
      ],
      "overall_sentiment_score": 0.124437,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.104198",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Assessing Oculis Holding (NasdaqGM:OCS) Valuation After FDA Backing for OCS\u201105 and PIONEER Program Progress",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocs/oculis-holding/news/assessing-oculis-holding-nasdaqgmocs-valuation-after-fda-bac/amp",
      "time_published": "20251223T020937",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Oculis Holding (NasdaqGM:OCS) has received FDA backing for its neuro-ophthalmology candidate OCS-05, allowing it to enter the PIONEER program with pivotal trials set for 2025 and 2026. Despite a significant year-to-date share price return and strong pipeline momentum, the stock is trading at a steep discount to analyst targets. However, its Price to Book ratio of 7.1x suggests it is overvalued compared to both peers and the broader pharmaceuticals industry, reflecting high market optimism for its late-stage pipeline.",
      "banner_image": "NULL",
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.900173"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.815899"
        },
        {
          "topic": "finance",
          "relevance_score": "0.601911"
        }
      ],
      "overall_sentiment_score": 0.101407,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.100179",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Advancing Privosegtor Toward PIONEER Registrational Trials Could Be A Game Changer For Oculis (OCS)",
      "url": "https://www.sahmcapital.com/news/content/advancing-privosegtor-toward-pioneer-registrational-trials-could-be-a-game-changer-for-oculis-ocs-2025-12-21",
      "time_published": "20251222T130951",
      "authors": [
        "Simply Wall St or NULL"
      ],
      "summary": "Oculis Holding AG is advancing its neuro-ophthalmology candidate privosegtor (OCS-05) toward PIONEER registrational trials, while also preparing additional clinical studies for licaminlimab in dry eye disease. This move follows positive FDA feedback and aims to strengthen Oculis's ophthalmology pipeline. The company faces significant financial risks due to ongoing losses and frequent equity raises, but the potential for new late-stage clinical readouts provides a sharpened catalyst map for investors.",
      "banner_image": "NULL",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.914975"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.730899"
        },
        {
          "topic": "finance",
          "relevance_score": "0.646424"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.610487"
        }
      ],
      "overall_sentiment_score": 0.096251,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.206934",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BLK",
          "relevance_score": "0.643296",
          "ticker_sentiment_score": "0.035797",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Advancing Privosegtor Toward PIONEER Registrational Trials Could Be A Game Changer For Oculis (OCS)",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocs/oculis-holding/news/advancing-privosegtor-toward-pioneer-registrational-trials-c",
      "time_published": "20251222T130901",
      "authors": [
        "Sasha Jovanovic"
      ],
      "summary": "Oculis Holding AG is moving its neuro-ophthalmology candidate, privosegtor (OCS-05), into registrational PIONEER trials following positive FDA feedback. This development, alongside planned studies for licaminlimab in dry eye disease, aims to strengthen Oculis's ophthalmology pipeline and enhance its investment narrative, despite ongoing financial risks associated with heavy losses and frequent equity raises. The progression adds significant late-stage trial catalysts, providing more clarity and potential upside for investors.",
      "banner_image": "https://images.simplywall.st/company/8e8ffc90-991b-449f-9cff-26836846d85f/chart/quote-price",
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.909164"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.719642"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.632329"
        }
      ],
      "overall_sentiment_score": 0.209419,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.336992",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BLK",
          "relevance_score": "0.627574",
          "ticker_sentiment_score": "0.120907",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABNB",
          "relevance_score": "0.584095",
          "ticker_sentiment_score": "0.050441",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADBE",
          "relevance_score": "0.590731",
          "ticker_sentiment_score": "0.127077",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.590502",
          "ticker_sentiment_score": "0.264201",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Advancing Privosegtor Toward PIONEER Registrational Trials Could Be A Game Changer For Oculis (OCS)",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocs/oculis-holding/news/advancing-privosegtor-toward-pioneer-registrational-trials-c/amp",
      "time_published": "20251221T140854",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Oculis Holding AG is advancing its neuro-ophthalmology candidate privosegtor (OCS-05) toward PIONEER registrational trials, following positive FDA feedback. This move, along with planned clinical studies for licaminlimab in dry eye disease, aims to strengthen Oculis's ophthalmology pipeline and sharpen its near-term catalyst map for investors. While this progression introduces significant potential rewards, it also highlights ongoing financing risks and the need for successful execution to justify a premium valuation amidst sustained unprofitability.",
      "banner_image": "NULL",
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.900254"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.818729"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.711835"
        }
      ],
      "overall_sentiment_score": 0.178026,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.275238",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BLK",
          "relevance_score": "0.620627",
          "ticker_sentiment_score": "0.142129",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Oculis stock price target raised to $40 by Stifel on neuro-ophthalmology progress",
      "url": "https://www.investing.com/news/analyst-ratings/oculis-stock-price-target-raised-to-40-by-stifel-on-neuroophthalmology-progress-93CH-4417329",
      "time_published": "20251220T130901",
      "authors": [
        "Investing.com"
      ],
      "summary": "Stifel has increased its price target for Oculis Holding AG (NASDAQ:OCS) to $40.00 from $35.00, maintaining a Buy rating due to the company's progress in neuro-ophthalmology. Oculis's neuro-ophthalmology asset, privosegtor, is advancing into late-stage development and demonstrated promising results in Phase 2 trials, leading to positive analyst sentiment despite current overvaluation compared to InvestingPro\u2019s Fair Value assessment. The company also announced plans to advance privosegtor into registrational PIONEER program, with pivotal trials for acute optic neuritis expected in Q4 2025 and Q1 2026.",
      "banner_image": "https://i-invdn-com.investing.com/news/international_newspapers_69x52._800x533_L_1419494241.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.932430"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.849935"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.725520"
        }
      ],
      "overall_sentiment_score": 0.459915,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "0.967631",
          "ticker_sentiment_score": "0.468780",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Oculis stock price target raised to $40 by Stifel on neuro-ophthalmology progress",
      "url": "https://za.investing.com/news/analyst-ratings/oculis-stock-price-target-raised-to-40-by-stifel-on-neuroophthalmology-progress-93CH-4036304",
      "time_published": "20251220T030852",
      "authors": [
        "NULL"
      ],
      "summary": "Stifel has raised its price target for Oculis Holding AG (NASDAQ:OCS) to $40 from $35, maintaining a Buy rating due to the company's progress in neuro-ophthalmology. Oculis's privosegtor asset is advancing into late-stage development, showing promising results in Phase 2 trials and aiming to be the first FDA-approved neuroprotection agent. Despite being considered overvalued by InvestingPro's fair value assessment, the company holds more cash than debt and has significant upcoming milestones in its clinical pipeline for 2026 and 2027.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_six_pile_69x52._800x533_L_1419494215.jpg",
      "source": "Investing.com South Africa",
      "category_within_source": "General",
      "source_domain": "Investing.com South Africa",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.904231"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.812955"
        }
      ],
      "overall_sentiment_score": 0.464697,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.481729",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Oculis stock price target raised to $40 by Stifel on neuro-ophthalmology progress",
      "url": "https://m.uk.investing.com/news/analyst-ratings/oculis-stock-price-target-raised-to-40-by-stifel-on-neuroophthalmology-progress-93CH-4425957?ampMode=1",
      "time_published": "20251219T140854",
      "authors": [
        "Investing.com"
      ],
      "summary": "Stifel raised its price target on Oculis Holding AG (NASDAQ:OCS) to $40.00 from $35.00, maintaining a Buy rating. The investment firm highlighted Oculis as an \"under-the-radar name\" advancing a differentiated neuro-ophthalmology asset, privosegtor, into late-stage development. Despite being considered overvalued by some metrics, the company's strong pipeline, financial flexibility, and upcoming clinical milestones, including pivotal studies for privosegtor and OCS-01, demonstrate significant promise.",
      "banner_image": "NULL",
      "source": "Investing.com UK",
      "category_within_source": "General",
      "source_domain": "Investing.com UK",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.928161"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.830330"
        }
      ],
      "overall_sentiment_score": 0.045681,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "0.307783",
          "ticker_sentiment_score": "0.026010",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "JPMorgan Initiates Coverage on Oculis Holding AG With Overweight Rating, $38 Price Target",
      "url": "https://www.marketscreener.com/news/jpmorgan-initiates-coverage-on-oculis-holding-ag-with-overweight-rating-38-price-target-ce7d50dddd81f026",
      "time_published": "20251219T122208",
      "authors": [],
      "summary": "JPMorgan has initiated coverage on Oculis Holding AG, a Switzerland-based biotechnology company focused on eye disease treatment, with an Overweight Rating and a $38 price target. The company's pipeline includes OCS-01 for diabetic macular edema, OCS-02 for dry eye disease, and OCS-05 for acute optic neuritis and other neuro-ophthalmic disorders. This news follows several recent developments for Oculis Holding AG, including earnings reports and advancements in their clinical trials.",
      "banner_image": "https://www.marketscreener.com/images/actions/th/cadenas.svg",
      "source": "marketscreener.com",
      "category_within_source": "General",
      "source_domain": "marketscreener.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.930626"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.826565"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.710629"
        },
        {
          "topic": "finance",
          "relevance_score": "0.616565"
        }
      ],
      "overall_sentiment_score": 0.413133,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.444427",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Oculis Holding AG (NASDAQ:OCS) Receives Consensus Rating of \"Moderate Buy\" from Analysts",
      "url": "https://www.marketbeat.com/instant-alerts/oculis-holding-ag-nasdaqocs-receives-consensus-rating-of-moderate-buy-from-analysts-2025-12-17/",
      "time_published": "20251217T134423",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Oculis Holding AG (NASDAQ:OCS) has received a \"Moderate Buy\" consensus rating from analysts, with six \"buy\" ratings and one \"sell\" rating, and an average one-year price target of $42.33. The company recently surpassed quarterly EPS expectations and focuses on clinical-stage ophthalmic biopharmaceuticals with lead candidate OCS-01 in Phase 3 trials for diabetic macular edema. Institutional investors have notably increased their holdings in OCS, reflecting growing interest in the company.",
      "banner_image": "https://www.marketbeat.com/logos/oculis-holding-ag-logo-1200x675.jpg?v=20230510063742",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.948944"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.837151"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.728142"
        }
      ],
      "overall_sentiment_score": 0.300878,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.528968",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.561308",
          "ticker_sentiment_score": "0.141568",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "(OCS) Movement as an Input in Quant Signal Sets",
      "url": "https://news.stocktradersdaily.com/news_release/17/OCS_Movement_as_an_Input_in_Quant_Signal_Sets_121325064402_1765669442.html",
      "time_published": "20251213T184400",
      "authors": [
        "Jesse F."
      ],
      "summary": "This article from Stock Traders Daily analyzes Oculis Holding Ag (NYSE: OCS), highlighting a mid-channel oscillation pattern and a significant 39.8:1 risk-reward short setup. It details AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014along with multi-timeframe signal analysis, indicating strong near and mid-term sentiment. The article suggests that if this strong sentiment persists, it could extend into the long term for OCS.",
      "banner_image": "https://news.stocktradersdaily.com/media/685437_OCS_graph.jpg",
      "source": "Stock Traders Daily",
      "category_within_source": "General",
      "source_domain": "Stock Traders Daily",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.921956"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.736277"
        }
      ],
      "overall_sentiment_score": 0.541187,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.534444",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities",
      "url": "https://uk.finance.yahoo.com/news/oculis-publishes-notifications-transactions-persons-210500545.html",
      "time_published": "20251210T150913",
      "authors": [],
      "summary": "The article \"Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities\" appears to be partially loaded or an empty content placeholder from Yahoo. The visible text primarily concerns Yahoo's cookie and privacy policy, mentioning that Yahoo is part of the Yahoo family of brands and detailing how cookies are used for site functionality, security, measurement, and personalized advertising. No actual content regarding Oculis or managerial transactions is present.",
      "banner_image": "https://s.yimg.com/rz/p/yahoo_frontpage_en-US_s_f_p_bestfit_frontpage.png",
      "source": "Yahoo Finance UK",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance UK",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.632421"
        }
      ],
      "overall_sentiment_score": 0.012049,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "0.320626",
          "ticker_sentiment_score": "0.037479",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities",
      "url": "https://finance.yahoo.com/news/oculis-publishes-notifications-transactions-persons-210500507.html",
      "time_published": "20251209T160500",
      "authors": [
        "NULL"
      ],
      "summary": "Oculis Holding AG announced the publication of notifications regarding transactions by persons discharging managerial responsibilities. These transactions relate to the vesting and settlement of Restricted Stock Units (RSUs) previously granted to the company's directors. The specific directors mentioned in the attachments are Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner.",
      "banner_image": "NULL",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.847585"
        }
      ],
      "overall_sentiment_score": 0.026144,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.042929",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities",
      "url": "https://www.globenewswire.com/news-release/2025/12/09/3202780/0/en/Oculis-Publishes-Notifications-of-Transactions-by-Persons-Discharging-Managerial-Responsibilities.html",
      "time_published": "20251209T160500",
      "authors": [],
      "summary": "Oculis Holding AG announced the vesting and settlement of Restricted Stock Units (RSUs) previously granted to its directors. This notification covers transactions for Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner. The company issued these notifications on December 9, 2025, detailing the RSU vests.",
      "banner_image": "https://ml-eu.globenewswire.com/media/MzdiZTQ1M2UtOGQ4Yy00Zjg2LTlmZTUtNzZhZTljNWM1Y2QyLTEyMDA1NzYtMjAyNS0xMi0wOS1lbg==/tiny/Oculis-Holding-AG.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.808479"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.629296"
        }
      ],
      "overall_sentiment_score": 0.01365,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.035199",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Wall Street Analysts Predict a 106.04% Upside in Oculis Holding AG (OCS): Here's What You Should Know",
      "url": "https://finance.yahoo.com/news/wall-street-analysts-predict-106-145501407.html",
      "time_published": "20251208T095500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "According to Wall Street analysts, Oculis Holding AG (OCS) has a mean price target indicating a potential 106% upside, based on a range of estimates from $29.00 to $55.07. This optimistic outlook is further supported by strong agreement among analysts on upward earnings estimate revisions for the company. Despite the inherent skepticism advised for price targets, the increased optimism and a Zacks Rank #2 (Buy) suggest potential for OCS.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/zf_1wpp4e4lihErpE5wvzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyNjtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2020-11/3bc15d30-250e-11eb-bffb-472fe5eb11fe",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.936901"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.936129"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.714641"
        },
        {
          "topic": "finance",
          "relevance_score": "0.603637"
        }
      ],
      "overall_sentiment_score": 0.441269,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.448659",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Wall Street Analysts Predict a 106.04% Upside in Oculis Holding AG (OCS): Here's What You Should Know",
      "url": "https://finviz.com/news/248479/wall-street-analysts-predict-a-10604-upside-in-oculis-holding-ag-ocs-heres-what-you-should-know",
      "time_published": "20251208T095500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Wall Street analysts are predicting a significant upside of 106.04% for Oculis Holding AG (OCS), with a mean price target of $44.67. While price targets alone can be misleading, strong agreement among analysts and positive earnings estimate revisions for OCS suggest potential for stock growth. The company currently holds a Zacks Rank #2 (Buy), indicating further upside potential.",
      "banner_image": "NULL",
      "source": "Finviz",
      "category_within_source": "General",
      "source_domain": "Finviz",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.932415"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.822802"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.709712"
        }
      ],
      "overall_sentiment_score": 0.482564,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.480240",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities",
      "url": "https://finance.yahoo.com/news/oculis-publishes-notifications-transactions-persons-210500246.html",
      "time_published": "20251204T160939",
      "authors": [],
      "summary": "Oculis Holding AG has published notifications regarding transactions by persons discharging managerial responsibilities. The notification specifically relates to the vesting and settlement of Restricted Stock Units (RSUs) previously granted to a director of the company on November 29, 2025. This information is provided as a paid press release from Zug, Switzerland.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/rj0Ta3GGeVAy26gXI.Thag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDtoPTQ4O2cfPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2025-08/b2b7bbc0-8385-11f0-977e-d9d7d4cd04d2",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.825342"
        }
      ],
      "overall_sentiment_score": 0.013783,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "0.308972",
          "ticker_sentiment_score": "0.030820",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Oculis (NASDAQ: OCS) discloses RSU vesting and settlement by company director",
      "url": "https://www.stocktitan.net/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-1tk6p6isyzcx.html",
      "time_published": "20251204T044328",
      "authors": [
        "NULL"
      ],
      "summary": "Oculis (NASDAQ: OCS) announced the vesting and settlement of restricted stock units (RSUs) previously granted to a director, Arshad Khanani. The RSUs vested on November 29, 2025, according to a notification published on December 3, 2025. The announcement did not specify the number of RSUs involved or whether the settlement was in cash or shares.",
      "banner_image": "https://static.stocktitan.net/company-logo/ocs.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.905011"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.711783"
        },
        {
          "topic": "finance",
          "relevance_score": "0.616230"
        }
      ],
      "overall_sentiment_score": 0.037827,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.035482",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "LifeSci Capital Initiates Coverage of Oculis Holding (OCS) with Outperform Recommendation",
      "url": "https://www.nasdaq.com/articles/lifesci-capital-initiates-coverage-oculis-holding-ocs-outperform-recommendation",
      "time_published": "20251204T044328",
      "authors": [
        "George Maybach"
      ],
      "summary": "LifeSci Capital has initiated coverage on Oculis Holding (OCS) with an \"Outperform\" recommendation. Analysts forecast a 138.07% upside, with an average one-year price target of $44.73/share. Institutional ownership in Oculis Holding increased significantly in the last quarter, with 34 funds reporting positions.",
      "banner_image": null,
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.949666"
        }
      ],
      "overall_sentiment_score": 0.485476,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.467074",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities",
      "url": "https://www.globenewswire.com/news-release/2025/12/03/3199331/0/en/oculis-publishes-notifications-of-transactions-by-persons-discharging-managerial-responsibilities.html",
      "time_published": "20251203T160500",
      "authors": [],
      "summary": "Oculis Holding AG announced the publication of a notification related to the vesting and settlement of Restricted Stock Units (RSUs) previously granted to a director, Arshad Khanani, on November 29, 2025. This notification was disclosed on December 3, 2025, from Zug, Switzerland. The company regularly publishes such notifications regarding transactions by persons discharging managerial responsibilities.",
      "banner_image": "https://ml-eu.globenewswire.com/media/NzllYjQ3M2QtYTc2YS00NjZmLWEzM2QtN2VjYmE2NmIyYmY0LTEyMDA1NzYtMjAyNS0xMi0wMy1lbg==/tiny/Oculis-Holding-AG.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.838326"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.710073"
        }
      ],
      "overall_sentiment_score": 0.01264,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.049515",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Oculis Holding AG Secures $110 Million in Oversubscribed Share Offering",
      "url": "https://www.tipranks.com/news/company-announcements/oculis-holding-ag-secures-110-million-in-oversubscribed-share-offering",
      "time_published": "20251110T160909",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Oculis Holding AG successfully secured $110 million in an oversubscribed share offering, with potential to reach $124.2 million if underwriters exercise their option. The proceeds will primarily fund the development of Privosegtor for optic neuropathies and support general corporate operations through late 2028. Despite a \"Neutral\" rating from TipRanks' AI Analyst due to weak financial performance, the company aims to strengthen its market position in neuro-ophthalmology.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1549769756-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.943327"
        }
      ],
      "overall_sentiment_score": 0.033886,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "0.336929",
          "ticker_sentiment_score": "0.044863",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Oculis Holding AG Announces Participation in Upcoming Investor Conferences to Showcase Late-Stage Pipeline Developments",
      "url": "https://www.quiverquant.com/news/Oculis+Holding+AG+Announces+Participation+in+Upcoming+Investor+Conferences+to+Showcase+Late-Stage+Pipeline+Developments",
      "time_published": "20251105T091100",
      "authors": [],
      "summary": "Oculis Holding AG will participate in several investor conferences in November 2025 to update on its late-stage clinical portfolio. Key developments include advancing Privosegtor into registrational trials, anticipating OCS-01 topline results for diabetic macular edema by Q2 2026, and launching a genotype-based trial for Licaminlimab in dry eye disease. The company aims to highlight its strong position and milestones to the investment community.",
      "banner_image": "https://www.quiverquant.com/images/ocs_rect_new.png",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.929926"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.708473"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.622678"
        }
      ],
      "overall_sentiment_score": 0.486677,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.460006",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Oculis Holding (OCS) Advances Privosegtor to Registrational Trials After FDA Meeting Will Innovation Leadership Strengthen?",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocs/oculis-holding/news/oculis-holding-ocs-advances-privosegtor-to-registrational-tr",
      "time_published": "20251016T192928",
      "authors": [
        "Simply Wall St",
        "Sasha Jovanovic"
      ],
      "summary": "Oculis Holding (OCS) is advancing its drug Privosegtor into registrational trials for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy after positive FDA feedback. This move, coupled with upcoming presentations at major ophthalmology conferences, is a pivotal step for Oculis to solidify its leadership in innovative ophthalmic therapies. The company faces ongoing challenges, including unprofitability and leadership changes, but the regulatory progress aims to reshape its investment narrative.",
      "banner_image": "https://images.ctfassets.net/n07nr2koi959/2zXqBK9eFqVJCGTQWhQWFX/c3400470ed0819d8056c9b1de6e897a0/Sasha_Jovanovic_-_Equity_Analyst.jpg?fit=thumb&w=64&h=64",
      "source": "simplywall.st",
      "category_within_source": "General",
      "source_domain": "simplywall.st",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.647885"
        }
      ],
      "overall_sentiment_score": 0.009157,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "0.301454",
          "ticker_sentiment_score": "0.015663",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewswire",
      "url": "https://www.globenewswire.com/news-release/2025/10/14/3166644/0/en/Oculis-Publishes-Notifications-of-Transactions-by-Persons-Discharging-Managerial-Responsibilities.html",
      "time_published": "20251014T200833",
      "authors": [],
      "summary": "Oculis Holding AG has published two notifications regarding transactions by a director. These notifications detail the exercise of vested stock options to purchase ordinary shares, followed by the subsequent sale of these shares. The transactions were conducted under a 10b5-1 trading plan, in compliance with SEC regulations.",
      "banner_image": null,
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.803733"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.707571"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.627939"
        }
      ],
      "overall_sentiment_score": 0.032407,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "0.335463",
          "ticker_sentiment_score": "0.048424",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - Stock Titan",
      "url": "https://www.stocktitan.net/news/OCS/oculis-publishes-notifications-of-transactions-by-persons-uh4aryt46jj9.html",
      "time_published": "20251014T200500",
      "authors": [],
      "summary": "Oculis (NYSE:OCS) disclosed that a director exercised vested stock options and subsequently sold the resulting ordinary shares, with filings dated October 14, 2025. These transactions were executed under a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934. The attached notifications reference C. Ackermann as the director involved in these transactions.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.817072"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.725938"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.536346"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.407296"
        }
      ],
      "overall_sentiment_score": 0.02927,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "0.301601",
          "ticker_sentiment_score": "0.034766",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Oculis Holding AG Highlights Innovative Late-Stage Pipeline at Eyecelerator and AAO Annual Meeting - Quiver Quantitative",
      "url": "https://www.quiverquant.com/news/Oculis+Holding+AG+Highlights+Innovative+Late-Stage+Pipeline+at+Eyecelerator+and+AAO+Annual+Meeting",
      "time_published": "20251014T081000",
      "authors": [],
      "summary": "Oculis Holding AG announced its late-stage product pipeline will be showcased at the Eyecelerator event and the American Academy of Ophthalmology (AAO) Annual Meeting. CEO Riad Sherif will provide updates on key developments including registrational trials for Privosegtor for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy, and Phase 3 investigations into OCS-01 for diabetic macular edema with results expected mid-2026. The company will also participate in several discussions, highlighting its advancements in ophthalmic care.",
      "banner_image": "https://www.quiverquant.com/images/ocs_rect_new.png",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.906931"
        },
        {
          "topic": "finance",
          "relevance_score": "0.610297"
        }
      ],
      "overall_sentiment_score": 0.040063,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "0.316736",
          "ticker_sentiment_score": "0.002724",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025 - Yahoo Finance",
      "url": "https://finance.yahoo.com/news/oculis-spotlight-transformative-stage-pipeline-080000766.html",
      "time_published": "20251014T080000",
      "authors": [],
      "summary": "Oculis Holding AG announced it will highlight its late-stage pipeline at Eyecelerator and the AAO 2025 meeting. Key updates include advancing Privosegtor into registrational trials for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy, expected Q2 2026 topline readouts for OCS-01 eye drops in diabetic macular edema, and the anticipated Q4 2025 start of the PREDICT-1 trial for Licaminlimab in dry eye disease. The company continues to focus on developing innovative treatments for ophthalmic and neuro-ophthalmic conditions.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/iuy6vbbeZZeiKgz96e65CQ--/YXBwaWQ9aGlnaGxhbmNlcjt3PTM2MDtoPTEyMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8aca71b5070568d4906f198837bc6857",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.019042,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "0.335653",
          "ticker_sentiment_score": "0.013531",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Privosegtor advancing to registrational trials \u2014 Oculis spotlights late-stage pipeline at AAO 2025 - Stock Titan",
      "url": "https://www.stocktitan.net/news/OCS/oculis-to-spotlight-transformative-late-stage-pipeline-at-d2974o32wn46.html",
      "time_published": "20251014T080000",
      "authors": [],
      "summary": "Oculis (Nasdaq: OCS) will highlight its late-stage ophthalmology pipeline at Eyecelerator and the AAO Annual Meeting in October 2025. Key updates include Privosegtor advancing to registrational trials for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy after positive FDA discussion, OCS-01 (DIAMOND Phase 3) with topline readouts expected in Q2 2026, and the PREDICT-1 registrational trial for Licaminlimab starting in Q4 2025. CEO Riad Sherif will present at Eyecelerator and Oculis will participate in various related events.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.010348,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "0.308555",
          "ticker_sentiment_score": "0.033578",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Chardan Capital Issues Positive Estimate for Oculis Earnings",
      "url": "https://www.marketbeat.com/instant-alerts/chardan-capital-issues-positive-estimate-for-oculis-earnings-2025-10-13/",
      "time_published": "20251013T052332",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Chardan Capital has increased its FY2025 EPS estimate for Oculis (NASDAQ:OCS) to ($2.73) and maintained a \"Buy\" rating with a $51.00 price target. The report highlights increased institutional investment in Oculis and provides an overview of the company's financial performance and product candidates. Oculis shares opened at $21.09, with a market capitalization of $920.79 million.",
      "banner_image": "https://www.marketbeat.com/logos/oculis-holding-ag-logo-1200x675.jpg?v=20230510063742",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.830578"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.739634"
        }
      ],
      "overall_sentiment_score": 0.008147,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "0.311992",
          "ticker_sentiment_score": "0.009916",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "OCS Stock Price and Chart \u2014 NASDAQ:OCS",
      "url": "https://www.tradingview.com/symbols/NASDAQ-OCS/",
      "time_published": "20241231T235959",
      "authors": [],
      "summary": "This article provides a detailed overview of Oculis Holding AG (OCS) stock performance, key financial metrics, and company information. It includes chart data for various timeframes, upcoming earnings details, and analyst ratings, alongside a company description and frequently asked questions about the stock.",
      "banner_image": null,
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.903330"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.815877"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.733699"
        }
      ],
      "overall_sentiment_score": 0.143811,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.113225",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Oculis releases positive phase 3 data from OPTIMIZE-1 trial for post-op inflammation and pain",
      "url": "https://glance.eyesoneyecare.com/stories/2024-04-15/oculis-releases-positive-phase-3-data-from-optimize-1-trial-for-post-op-inflammation-and-pain/",
      "time_published": "20241231T235959",
      "authors": [
        "Alex Delaney-Gesing"
      ],
      "summary": "Oculis S.A. announced positive phase 3 data from its OPTIMIZE-1 study for OCS-01 eye drops, demonstrating significant reduction in inflammation and pain after cataract surgery. OCS-01, a highly concentrated dexamethasone formulation using OPTIREACH technology, showed superiority over placebo with a favorable safety profile. Further trials, including OPTIMIZE-2 and DIAMOND studies for diabetic macular edema, are ongoing, with an eventual new drug application submission planned.",
      "banner_image": null,
      "source": "Eyes On Eyecare",
      "category_within_source": "General",
      "source_domain": "Eyes On Eyecare",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.908185"
        }
      ],
      "overall_sentiment_score": 0.8075,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.838613",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Oculis to Present at the Stifel 2024 Healthcare Conference",
      "url": "https://www.globenewswire.com/news-release/2024/11/13/2979960/0/en/Oculis-to-Present-at-the-Stifel-2024-Healthcare-Conference.html",
      "time_published": "20241113T040000",
      "authors": [],
      "summary": "Oculis Holding AG announced that its management will participate in the Stifel 2024 Healthcare Conference on November 18-19, 2024. Sylvia Cheung, CFO, will host a fireside chat on November 18, 2024, at 3:35 pm ET, with a live webcast available. The company will also be available for one-on-one meetings with interested investors.",
      "banner_image": null,
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.947148"
        },
        {
          "topic": "finance",
          "relevance_score": "0.724760"
        }
      ],
      "overall_sentiment_score": 0.178674,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.242998",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "STZ",
          "relevance_score": "0.605541",
          "ticker_sentiment_score": "0.104624",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Inaugural Ramin Tadayoni Award will be granted at 2024 EURETINA Congress",
      "url": "https://europe.ophthalmologytimes.com/view/inaugural-ramin-tadayoni-award-will-be-granted-at-2024-euretina-congress-oculis-retina",
      "time_published": "20240627T000000",
      "authors": [
        "Hattie Hayes"
      ],
      "summary": "The European Society of Retina Specialists (EURETINA), supported by Oculis, has established the Ramin Tadayoni Award in memory of their late president and Oculis CSO, Ramin Tadayoni, MD, PhD. This annual award will recognize outstanding contributions and exceptional potential in retina research, granting \u20ac30,000 for research support and an additional \u20ac5,000 directly to the candidate. The inaugural award will be presented at the 2024 EURETINA Congress, and applications are open until July 29, 2024.",
      "banner_image": null,
      "source": "Ophthalmology Times Europe",
      "category_within_source": "General",
      "source_domain": "Ophthalmology Times Europe",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.915494"
        }
      ],
      "overall_sentiment_score": 0.328073,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.330821",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market",
      "url": "https://www.stocktitan.net/news/OCS/oculis-announces-closing-of-registered-direct-offering-and-a89gh2ml6fbx.html",
      "time_published": "20240422T083400",
      "authors": [],
      "summary": "Oculis Holding AG announced the closing of its registered direct offering, raising $59 million through the sale of 5,000,000 ordinary shares. The company's shares will also begin trading on the Nasdaq Iceland Main Market under the ticker \"OCS\" starting April 23, 2024, making it the second company to dual-list in the U.S. and Iceland. Oculis also confirmed its Phase 2b RELIEF trial for OCS-02 in Dry Eye Disease is on track to report results in Q2 2024.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "ipo",
          "relevance_score": "0.926439"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.806683"
        },
        {
          "topic": "finance",
          "relevance_score": "0.710380"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.701472"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.634628"
        }
      ],
      "overall_sentiment_score": 0.294008,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.317965",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NDAQ",
          "relevance_score": "0.612497",
          "ticker_sentiment_score": "0.202617",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Oculis announces completion of oversubscribed USD 59 million registered direct offering",
      "url": "https://ggba.swiss/en/oculis-announces-completion-of-oversubscribed-usd-59-million-registered-direct-offering/",
      "time_published": "20240415T000000",
      "authors": [],
      "summary": "Oculis, a Vaud-based biopharma company, announced the completion of an oversubscribed registered direct offering, raising USD 59 million. This funding will extend its operations into 2026 and follows a successful listing on NASDAQ Iceland Main Market, making Oculis dual-listed in the U.S. and Iceland. The proceeds will advance Oculis\u2019s clinical development pipeline for transformative eye disease therapies.",
      "banner_image": null,
      "source": "Greater Geneva Bern area",
      "category_within_source": "General",
      "source_domain": "Greater Geneva Bern area",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.922527"
        },
        {
          "topic": "finance",
          "relevance_score": "0.823455"
        }
      ],
      "overall_sentiment_score": 0.879046,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.861309",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Oculis releases positive results from Phase 3 OPTIMIZE-1 trial of OCS-01 for treatment of inflammation, pain after cataract surgery",
      "url": "https://www.ophthalmologytimes.com/view/oculis-releases-positive-results-from-phase-3-optimize-1-trial-of-ocs-01-for-treatment-of-inflammation-pain-after-cataract-surgery",
      "time_published": "20240408T000000",
      "authors": [
        "David Hutton"
      ],
      "summary": "Oculis Holding AG announced positive results from its Phase 3 OPTIMIZE-1 trial of OCS-01 for treating inflammation and pain after cataract surgery. The trial showed significant improvements with OCS-01 compared to a vehicle, with 57.2% of patients inflammation-free at Day 15 and 75.5% pain-free at Day 4. These results were presented at the 2024 ASCRS Annual Meeting, and a second Phase 3 trial readout is anticipated later this year to support an NDA submission.",
      "banner_image": null,
      "source": "Ophthalmology Times",
      "category_within_source": "General",
      "source_domain": "Ophthalmology Times",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.82619,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.825399",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Oculis announces positive top line results from Phase 3 trial of OCS-01 drops for diabetic macular edema",
      "url": "https://www.ophthalmologytimes.com/view/oculis-announces-positive-top-line-results-from-phase-3-trial-of-ocs-01-drops-for-diabetic-macular-edema",
      "time_published": "20230522T152010",
      "authors": [
        "David Hutton"
      ],
      "summary": "Oculis announced positive top line results from Stage 1 of its Phase 3 DIAMOND trial for OCS-01 eye drops in diabetic macular edema (DME). The trial met its primary and secondary endpoints with statistical significance, showing strong visual gain and a decrease in retinal thickness. OCS-01, a topical formulation of dexamethasone, is positioned as a potential first-line treatment and complement to existing therapies due to its non-invasive nature.",
      "banner_image": null,
      "source": "Ophthalmology Times",
      "category_within_source": "General",
      "source_domain": "Ophthalmology Times",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.924486"
        }
      ],
      "overall_sentiment_score": 0.218979,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OCS",
          "relevance_score": "0.348645",
          "ticker_sentiment_score": "0.006290",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.625476",
          "ticker_sentiment_score": "0.307865",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.646821",
          "ticker_sentiment_score": "0.238703",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.601725",
          "ticker_sentiment_score": "0.248302",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.616097",
          "ticker_sentiment_score": "0.207078",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    }
  ]
}